Member Info for Reckoner

When these options are eventually exercised they will represent 0.065% of the company's current share issue.
Nothing to see here.

That must be a fundamental cause. So far today there have been 7 trades totalling only £25k and yet the SP is jumping around fairly significantly. Once we get more attention the spread should reduce and also the volatility. Having said that, I'm not much bothered about these day-to-day movements.

aid & mystery
I suggest you read the RNSs and the 4D website as a minimum before investing here.
The NASDAQ listing provides access to more sophisticated investors who should be able to deliver the capital investment required to fund their drug development projects. If any one of these projects is successful the SP could rise very significantly. However, that is for the longer term. In the short term the SP movement is anyone’s guess.

It’s partly down to the relatively small proportion of shares in free float. In other words, the proportion of shares available for public trading is low (about 30%) thanks to much of the share capital being locked in with directors, institutions and some of the private investors who bought in at IPO. There are also agreements in place for many of these holders to sell their shares via a particular broker, the inconvenience of which might further discourage them from selling.
On top of this, there are only 3 market makers for ABDX compared to, say, Avacta which I think has 9.
So there are less tradeable shares available than with other similar sized companies, less current investors wanting to sell, or even able to sell, and less competition for the MMs to feel the need to reduce their spread.
However, you will often find that the Ask quote is reduced a few pence when you try to buy.

It’s a relatively illiquid stock thanks to a small proportion of shares in free float and some IPO investors locked in. This makes for a wide spread which deters many shorter-term investors, hence the lack of interest, both in the share itself and in the LSE board.
Then there’s the bad press about the ABC-19 agreement.
And all the good news around AVCT and ODX taking would-be investors away.
I’m in all three and think ABDX is a very good prospect at the current SP, but less so than the others. AVCT is a completely different proposition and my largest holding. If, as seems likely, AVCT LFTs take off, ABDX becomes derisked to some extent and should improve, thanks to the manufacturing agreement.

I meant 15% of IP's portfolio, of course.

It WAS 15% of their holding, not of AVCT, at end of 2019. It isn't now as they massively reduced their holding last year.
Nothing to see here.

No, I’m 56.

Similar to baldingquickly, I had my first (AZ) jab Monday having had Covid in December. Felt a little rough yesterday but no big deal.

The samples have to be taken by specialists.
It's aimed at emergency care settings.
It's nowhere near approved.
There doesn't appear to be any manufacturing capacity geared up for it.
Forget about it for now.

Sampling to be done by specialists in emergency care situations. So not a competitor to Avacta.

https://www.connexionfrance.com/French-news/10-minute-mobile-phone-Covid-tests-developed-in-France

Yes, Covid stocks are part of the wider group that some investors have sought better returns from during the pandemic. This includes the biotech and diagnostics sector, mining, technology and other regions such as China. When there’s optimism about a return to normality they swing out from these and back into the more traditional ones that will now seem undervalued, such as live entertainment or travel.
Interesting item on 100% margin rates - I wasn’t aware of that. But it doesn’t explain why some small caps are doing so well today.
As long as we’ve picked the right individual companies, we should be ok in the longer term, regardless of what sector we are invested in.

This has happened several times with Covid stocks since last summer.
Anytime there is a sense of optimism about ending restrictions.
I think it’s the short-term traders fleeing the Covid opportunity and putting their money elsewhere, e.g. transport. Then the reality sinks in that we still need testing as a key part of getting out of this. So the money comes back in. I’ve topped up ABDX, AVCT and ODX today. Hope I’m right.

A further amendment to the HuffPost article clarifies things a little:
"A previous version of the Avacta test, which relied on saliva rather than nasal swabs, did not pass testing by Porton Down last month. However, the latest updated version has shown excellent preliminary results and is currently being assessed."

I think that liquidity causes a problem at present.
A relatively small proportion of ABDX shares are free float and there are lock-in and orderly market agreements in place for some of those who invested through IPO. These limit when you can sell your holding and which broker you have to use.
This in turn helps to create the wide spread which is off-putting to many investors, particular those with shorter time horizons who are responsible for much AIM trading activity and noise on the bulletin boards. So you don’t get that same buzz here. Yet.
As well as the liquidity problem, we’ve also had downward pressure from negative media coverage of the RTC/ABC-19 government agreement.
However, given the much more positive news on government testing plans, this must be an attractive investment, even with this spread. If it isn’t then I’ve missed something.
I suspect when this starts to move the rise will be rapid, the spread will reduce and this will pull in more of the short-termers as well as the longer-term investors.

It’s easy to forget that we are in the middle of a period of massive change. For healthcare, for industry, for government, for how we go about our daily lives with each other at work and socially. In such times it is the highly adaptable who not only survive but positively thrive, whether we’re talking about institutions or individuals, companies or investors.

Omega Diagnostics and some other Life Science companies are constantly having to adjust to changes in the course of the pandemic, the scientific understanding of what to do about it and the government’s responses to this. Omega have just announced an agreement with a government that is committed to spending an eye-watering amount on testing. Testing which is vital if we are to properly open up the economy and our social lives, regardless of what happens with developments in vaccines or treatments. Testing which will also be needed in numerous other countries. Omega are one of the very few UK manufacturers who can capitalise on this need for rapid testing worldwide.

Successful investors will also need to show flexibility at the moment. So I suggest people don’t get so hung up on the inevitable changes to plans or messages during this period of flux. Don’t worry so much that a deadline has passed or a particular test hasn’t worked out. Disregard the latest trading figures which have very little bearing on what is about to happen. Don’t pick away at every loose thread as though these were normal times. Stick to the bigger picture and to the bigger changes that bode well, such as the ongoing recruitment drive.

If you aren’t convinced that ODX will thrive, despite all the positive signs, then I suggest you simply sell up and put your money somewhere you think is a better bet. You might turn out to be right. But you can’t know for sure. And I guess that is why so many spend so much time on here sharing their insecurities about it.

Each time the ODX price drops significantly, I’ve sold something else and topped up my holding. The same with several other Life Science stocks. The more I see of what ODX are doing, the more I perceive them to be one of those companies which will do very well out of the current chaos.

https://twitter.com/OmegaDiagnostic/status/1359873717090865158

I believe the inclusion of the trading update in today's RNS is a way of saying Goodbye to the old ODX and Hello to the new one.
No point in a retrospective trading update once ODX is knocking out millions of LFTs, so best get it out the way now.

Difficult to take seriously when it talks of “rapid inspections of up to 2 meters per day” and “increase its lateral flow test production capacity to 2 meters per week”.

No, it doesn't appear to be available on Degiro at the moment. Perhaps it will become so in future.
I bought ABDX via Charles Stanley Direct, which is quite a pricey platform.

My wife works in a school and self-tests weekly with the Innova LFT.